

## **Product datasheet**

# anti-PD-L1 rabbit monoclonal, IHC411, purified

#### Short overview

**Cat. No.** 691736 **Quantity** 1 ml

## **Product description**

HostRabbitAntibody TypeMonoclonalIsotypeIgGCloneIHC411

Immunogen Recombinant Human PD-L1

Formulation Tris pH 7.3-7.7 with 1% BSA and 0.09% sodium azide

UniprotID Q9NZQ7 (Human)

Synomym Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1,

B7 homolog 1, B7-H1, CD antigen CD274, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1

Conjugate Unconjugated

**Purification** Affinity chromatography

Storage 2-8°C

Intended use Research use only

Application IHC Reactivity Human

## **Applications**


Immunohistochemistry (IHC) - paraffin

1:50-1:200 (microwave treatment recommended)

#### Background

Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.

### **Product images**



Lung